Search companies or stocks...
Barinthus Biotherapeutics plc (BRNS) intrinsic value snapshot: our valuation models currently suggest the stock is undervalued, with an estimated 1366.4% upside relative to fair value at a market price of $0.71. Unlock the dollar fair value estimate for Barinthus Biotherapeutics plc with Tickerplace Pro.
Current Price: $0.71
Valuation: Undervalued
Confidence: 9.5/10
How we calculate fair value: We combine DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models to estimate intrinsic value. This figure is for information only - not investment advice - and assumptions may not reflect actual market conditions. We encourage doing your own research or speaking with a financial advisor before making investment decisions.
Search our company database (same as the site header), pick a match, or type a ticker to open its intrinsic value analysis.
The verdict and fair-value gap for Barinthus Biotherapeutics plc (BRNS) are summarised in the intrinsic value snapshot above. This section explains the method: we compare the live market price with modeled fair value using DCF, P/E Multiple, and P/S Multiple approaches. Assumptions can change with new earnings, growth, and discount-rate inputs, so treat the result as a research aid rather than a buy or sell signal. Tickerplace Pro unlocks the dollar fair value used in that comparison.
Use this section for context around the gap, not a third restatement of the top-line verdict. The free snapshot above already shows the percentage gap and market price; the dollar intrinsic value stays behind Tickerplace Pro. Compare BRNS with related intrinsic-value pages listed below (INMB, KZR, B, and more) to see how peers are framed on the same models.
Our models calculate the intrinsic value of Barinthus Biotherapeutics plc (BRNS) using DCF, P/E Multiple, and P/S Multiple approaches based on projected cash flows, growth rate, and discount rate. Sign in to Tickerplace Pro to view the full dollar estimate.
Based on our 2026 valuation models, BRNS appears undervalued at its current price of $0.71. Our model suggests 1366.4% upside potential.
Tickerplace calculates BRNS's intrinsic value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We project future cash flows, apply a discount rate that reflects investment risk, and compare the resulting fair value estimate to the current market price.
Peers for BRNS: open their intrinsic value pages.
